<div id="readability-page-1"><p>Squarepoint Ops LLC reduced its position in  Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 32.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 33,324 shares of the company's stock after selling 15,865 shares during the period. Squarepoint Ops LLC's holdings in Kymera Therapeutics were worth $1,454,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Kymera Therapeutics</strong> alerts:</span></p></div><ul><li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li></ul><p>Other institutional investors and hedge funds have also recently bought and sold shares of the company. Farther Finance Advisors LLC raised its holdings in  Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock valued at $27,000 after buying an additional 540 shares during the period.  PNC Financial Services Group Inc. raised its stake in shares of  Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock valued at $40,000 after acquiring an additional 770 shares during the period.  Raymond James Financial Inc. purchased a new position in shares of  Kymera Therapeutics in the 2nd quarter valued at $73,000.  Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of  Kymera Therapeutics by 15.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company's stock valued at $110,000 after acquiring an additional 343 shares in the last quarter.  Finally, Lazard Asset Management LLC purchased a new stake in  Kymera Therapeutics during the 2nd quarter worth $116,000. </p><h2>Insider Transactions at Kymera Therapeutics</h2><p>In other news, Director Jeffrey W. Albers sold 5,000 shares of the company's stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $89.76, for a total value of $448,800.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jared Gollob sold 49,307 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $88.67, for a total transaction of $4,372,051.69. Following the transaction, the insider directly owned 109,992 shares in the company, valued at $9,752,990.64. The trade was a 30.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 488,585 shares of company stock valued at $41,408,199 over the last ninety days. 16.01% of the stock is currently owned by corporate insiders. </p><h2>Wall Street Analyst Weigh In</h2><p>Several research analysts have commented on the company. B. Riley raised their price objective on Kymera Therapeutics from $60.00 to $80.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, October 24th. UBS Group upgraded Kymera Therapeutics to a &#34;strong-buy&#34; rating in a report on Thursday, December 4th. BTIG Research  set a $138.00 price target on Kymera Therapeutics in a research report on Monday, December 8th. Citigroup increased their price objective on shares of Kymera Therapeutics from $80.00 to $110.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, December 9th. Finally, Stephens lifted their price objective on shares of Kymera Therapeutics from $65.00 to $110.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued  a Buy rating and one  has given a Sell rating to the stock. According to data from MarketBeat.com, the company  has an average rating of &#34;Buy&#34; and a consensus target price of $114.45.</p><p><b>View Our Latest Stock Analysis on Kymera Therapeutics</b></p><h2>Kymera Therapeutics Stock Up 5.5%</h2><p>Shares of NASDAQ KYMR opened at $83.99 on Friday. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The business has a 50 day moving average price of $67.39 and a two-hundred day moving average price of $53.63. The firm has a market cap of $6.04 billion, a PE ratio of -23.40 and a beta of 2.28. </p><p>Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The business had revenue of $2.76 million during the quarter, compared to analyst estimates of $23.15 million.  On average, analysts anticipate that  Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year. </p><h2>Kymera Therapeutics Profile</h2> (Free Report)<p>Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.  </p><p>The company's pipeline emphasizes immunology and oncology.</p><h2>See Also</h2><ul><li>Five stocks we like better than Kymera Therapeutics</li><li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li><li>Most active stocks: Dollar volume vs share volume</li><li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li><li>Stock Dividend Cuts Happen Are You Ready?</li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lNUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lNUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Kymera Therapeutics Right Now?</h2><p>Before you consider Kymera Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.</p><p>While Kymera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KYMR

<p>Squarepoint Ops LLC reduced its stake in Kymera Therapeutics by 32.3% in Q2. Despite this, several analysts have given Kymera a 'buy' or 'strong-buy' rating, with price targets ranging from $80 to $138. The stock has a consensus target price of $114.45 and recently rose 5.5% to $83.99. Insider transactions and other institutional investments were also noted.</p>

Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR